

## topikale calcineurinhæmmere overhovedet er forbundet med øget risiko for nogen form for kræft.

**KORRESPONDANCE:** *Mette Deleuran*, Dermatologisk Afdeling S, Århus Universitetshospital, Århus Sygehus. E-mail: m.deleuran@dadlnet.dk

**ANTAGET:** 26. februar 2009

**INTERESSEKONFLIKTER:** *Kristian Thestrup-Pedersen* har fungeret som advisor for Astellas-Pharma Nordic, Novartis Basel, LEO-Pharma og er formand for *Drug Safety Monitoring Board, Basel and New Jersey*. Ingen af forfatterne ejer aktier i de firmaer, der producerer pimecrolimus og tacrolimus.

### LITTERATUR

- Olesen AB, Bang K, Juul S et al. Stable incidence of atopic dermatitis among children in Denmark during the 1990s. *Acta Derm Venereol* 2005;85:244-7.
- Mortz CG, Lauritsen JM, Bindslev-Jensen C et al. Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases. *Br J Dermatol* 2001;144:523-32.
- Williams HC, Strachan DP. The natural history of childhood eczema. Observations from the British 1958 birth cohort study. *Br J Dermatol* 1998;139:834-9.
- Flohr C, Weiland SK, Weinmayr G et al. The role of atopic sensitization in flexural eczema: Findings from the International Study of Asthma and Allergies in Childhood Phase Two. *J Allergy Clin Immunol* 2008;121:141-7.
- Herd RM, Tidman MJ, Prescott RJ et al. Prevalence of atopic eczema in the community: the Lothian Atopic Dermatitis study. *Br J Dermatol* 1996;135:18-9.
- Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. *Br J Dermatol* 2002;147:528-37.
- Berth-Jones J, Damstra RJ, Golsch S et al. Multinational Study Group. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. *Br Med J* 2003;326:1367.
- Hoetzenecker W, Ecker R, Kopp T et al. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. *J Allergy Clin Immunol* 2005;115:1276-83.
- Kauffman HM, Cherikh WS, McBride MA et al. Post-transplant de novo malignancies in renal transplant recipients. The past and present. *Eur Soc Organ Transplant* 2006;19:607-20.
- Sandilands A, Smith FJ, Irvine AD et al. Filaggrin's fuller figure: a glimpse into the genetic architecture of atopic dermatitis. *J Invest Dermatol* 2007;127:1282-4.
- Wu K, Higashi N, Hansen ER et al. Telomerase activity is increased and telomere length shortened in T cells from blood of patients with atopic dermatitis and psoriasis. *J Immunol* 2001;165:4742-7.
- Olesen AB, Engholm G, Storm HH et al. The risk of cancer among patients previously hospitalized for atopic dermatitis. *J Invest Dermatol* 2005;125:445-9.
- Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. *J Invest Dermatol* 2005;124:505-13.
- Pittelkow MR, Perry HO, Muller SA et al. Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study. *Arch Dermatol* 1981;117:465-8.
- Pion JA, Koenig KL, Lim HW. Is dermatological usage of coal tar carcinogenic? A review of the literature. *Dermatol Surg* 1995;21:227-31.
- Eriksson NE, Mikoczy A, Hagmar L. Cancer incidence in 13811 patients' skin tested for allergy. *J Invest Allergy Clin Immunol* 2005;15:161-6.
- Hagströmer L, Ye W, Nyrén O et al. Incidence of cancer among patients with atopic dermatitis. *Arch Dermatol* 2005;141:1123-7.
- Wang H, Diepgen TL. Atopic dermatitis and cancer risk. *Br J Dermatol* 2006;154:205-10.
- Alomar A, Berth-Jones J, Bos JD et al. The role of topical calcineurin inhibitors in atopic dermatitis. *Br J Dermatol* 2004;151:3-27.
- Reitamo S, Wollenberg A, Schöpf E et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. *Arch Dermatol* 2000;136:999-1006.
- Kauffman HM, Cherikh WS, McBride MA et al. Post-transplant de novo malignancies in renal transplant recipients: the past and present. *Transpl Int* 2006;19:607-20.
- Papp KA, Breuer K, Meurer M et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. *J Am Acad Dermatol* 2005;52:247-53.
- Stiehm ER, Roberts RL, Kaplan MS et al. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. *J Am Acad Dermatol* 2005;53:S206-13.
- Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. *Br J Dermatol* 2003;149:960-7.
- Lerche CM, Philipsen PA, Poulsen T et al. Topical tacrolimus in combination with simulated solar radiation does not enhance photocarcinogenesis in hairless mice. *Exp Dermatol* 2008;17:57-62.
- Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. *Dermatology* 2007;214:289-95.
- Naylor M, Elmets C, Jaracz E et al. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. *J Dermatolog Treat* 2005;16:149-53.
- Barbier N, Paul C, Luger T et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. *Br J Dermatol* 2004;150:96-102.
- Arellano FM, Wentworth CE, Arana A et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. *J Invest Dermatol* 2007;127:808-16.



## LÆGEMIDDELSTYRELSEN

### TILSKUD TIL LÆGEMIDLER

Lægemedelstyrelsen meddeler, at der pr. 27. juli 2009 ydes generelt tilskud efter sundhedslovens § 144 til følgende lægemidler:

- (N-06-AB-10) Escitalopram »Teva« tabletter\*, Teva Denmark A/S  
 (C-07-AB-02) Metoprololsuccinat »Actavis« depottabletter\*, Actavis Nordic A/S  
 (N-05-AX-08) Risperidon »Teva« smeltetabletter\*, Teva Denmark A/S  
 (N-06-AB-06) Sertralin »Actavis« tabletter\*, Actavis A/S  
 (G-04-BD-08) Vesicare tabletter\*, Singad Pharma ApS  
 (A-10-BX-07) Victoza injektionsvæske, Novo Nordisk A/S

gruppe uden klausulering over for bestemte sygdomme.

- (D-01-AE-16) Loceryl medicinsk neglelak\*, Orifarm A/S

gruppe klausuleret til personer, der modtager pension efter lov om social pension eller til personer, der er omfattet af følgende tilskuds-klausul:

Negleinfektioner forårsaget af amorolfinfølsomme svampe.

En betingelse for at opnå tilskud efter tilskudsklausulen er, at lægen har skrevet »tilskud« på recepten.

Denne bestemmelse træder i kraft den 27. juli 2009.

\* Omfattet af tilskudsprissystemet.